[ad_1]
Original title: 200 yuan / branch! Emergency vaccination of the new corona vaccine opens the first batch of Kexing biological supply to society
China Times reporter (chinatimes.net.cn) Sun Yuanyu Yujin reports from Beijing
With the news that Zhejiang Province has promoted the opening to society of the new corona vaccine emergency vaccination appointment platform, the issue of the new corona vaccine has heated up again. On October 21, the two issues of “New corona vaccine in Shaoxing, Zhejiang, 200 yuan per injection” and “Estimated annual production capacity of 610 million doses of China’s new corona vaccine by the end of the year “were posted on the Weibo search list.
On October 20, the emergency vaccination instructions for the new autumn and winter corona vaccine were released in Shaoxing, Zhejiang, and the online platform for registration of vaccination appointments was also opened to the public. The Zhejiang Jiaxing Center for Disease Control and Prevention posted “Instructions on New Coronary Vaccination” on WeChat public account on October 15. The article mentioned that according to the relevant requirements of the higher authorities, emergency vaccination of new corona vaccines should be prioritized in key populations, epidemic areas, safe and informed vaccination Carried out on a voluntary basis.
According to a China Times reporter, in addition to Shaoxing, Zhejiang Province has started scheduling appointments for the new vaccination crown, Jiaxing, Yiwu and other cities have also started appointments. Among them, Yiwu became the first vaccination site in China. The vaccine arrived in Yiwu on October 16. The group of personnel preparing to go abroad completes the vaccination. The manufacturer of the new corona vaccine used in this emergency vaccination in Zhejiang Province is Beijing Kexing Zhongwei Biotechnology Co., Ltd. (hereinafter “Kexing Bio”).
Cost-based pricing
According to the emergency vaccination instructions for the new autumn and winter vaccination wreath issued by Shaoxing, Zhejiang, on October 20, vaccination is divided into 2 doses, with a recommended interval of 28 days, from 18 to 59 years; the price is 200 yuan per bottle (bottle), and vaccination services are charged separately. The fee is 28 yuan per dose; Emergency vaccination objects are divided into key guarantee objects (medical personnel, health and epidemic prevention personnel, etc.), key recommendation objects (service personnel in public places, etc.) and general objects (other groups voluntary inoculation).
For the price of 200 a piece, the general online public commented that it was “very cheap.” Previously, when the price of the new corona vaccine was not yet clear, according to an interview with Sinopharm Group China Biotechnology Co., Ltd. and Kexing Biotechnology by a China Times reporter, it was estimated that the price of the two vaccines did not it would exceed 1,000 yuan.
At a press conference on the Joint Prevention and Control Mechanism of the State Council on October 20, Zheng Zhongwei, director of the Center for Scientific and Technological Development of the National Health Commission, said that the price of the new vaccine of China’s crown adheres to the main corporate prices, but adheres to the following principles: first, the principle of public attributes of the product, price It should not be based on supply and demand as the basis for pricing, but on cost as the basis for pricing; second, pricing is based on public willingness to inoculate and demand for vaccination for the new corona vaccine. Therefore, the price of the new Chinese crown vaccine should be within the acceptable range for the public.
Yiwu City, Zhejiang Province, has completed a batch of emergency vaccines for the new corona vaccine. According to a China Times reporter on October 17, in Yiwu City, non-resident residents who meet vaccination requirements can also get vaccinated. If there is local health insurance, 28 yuan The vaccination service fee can be reimbursed by health insurance.
The new corona vaccine for emergency vaccination in Zhejiang province was mainly purchased from Kexing Biotechnology. Jiaxing CDC previously announced that: “The new corona vaccine currently used for emergency vaccination in our city is unified by the provincial department to Beijing Kexing Zhongwei Biotechnology Co., Ltd. It is requested and distributed level by level by the company. to designated vaccination units. The vaccine has not been officially registered for the market and has been approved for emergency vaccination in accordance with the law. “Public information shows that the agency responsible for the phase I / II clinical research of the new corona vaccine is Jiangsu Province. Center for Disease Control and Prevention (Jiangsu Provincial Public Health Research Institute).
Production capacity exceeded 600 million doses at the end of the year
According to Zheng Zhongwei, China’s vaccine production capacity is expected to reach 610 million doses by the end of this year. Next year, the annual production capacity of the new Chinese crown vaccine will be effectively expanded on this basis to effectively meet the needs of China and other countries in the world for the new Chinese crown vaccine.
On October 21, Kexing Biotech spokesperson Liu Peicheng introduced to the China Times reporter that at the end of March 2020, Kexing Zhongwei Company was actively promoting vaccine development and at the same time began construction of the new industrialization of the crown vaccine, in national joint prevention and control. With the support of the mechanism’s vaccination team and the Beijing municipal government, the company completed the construction of the production line and its supporting facilities to a high standard in July. After expert evaluation and approval by the relevant departments, the production line was put into operation in August and mass production started. The production line has an annual production capacity of more than 300 million doses of the new corona vaccine and is expected to produce 100 million doses of vaccine (including semi-finished products) by the end of this year. We have determined the vaccine manufacturing and verification procedures, and the produced vaccines can meet international quality standards and quality requirements of China and vaccine-demanding countries.
Tian Baoguo, deputy director of the Department of Science and Technology for Social Development at the Ministry of Science and Technology, said that the four new Chinese coronavirus vaccines that have entered phase III clinical trials have received a total of about 60,000 subjects. and have received no reports of serious adverse reactions. The results of phase III clinical trials are an internationally recognized indicator of efficacy to verify the protection of vaccines. Tian Baoguo introduced that any type of vaccine, whether in the clinical trial stage or the large-scale post-marketing use stage, can have adverse reactions. The new coronavirus vaccine currently entering phase III clinical trials has basically mild adverse reactions, such as local pain, redness and swelling at the injection site, as well as transient low-grade fever and fever.
Liu Jingzhen, chairman and party secretary of Sinopharm Group, said the two inactivated vaccines from the Beijing Institute of Biological Products and the Wuhan Institute of Biological Products, which are affiliated with Sinopharm Sinopharm, are conducting phase III clinical trials. in 10 countries, and more than 50,000 have been inoculated. people. At present, China National Biotechnology Co., Ltd. is ready for large-scale production. Two high-level biosafety production workshops have been built for the new corona vaccine, the Beijing Institute of Biological Products and the Wuhan Institute of Biological Products. The production capacity will reach 1 billion doses next year, which ensures sufficient safety. Vaccine supply.
Massive information, accurate interpretation, all in the Sina Finance APP
Editor in Charge: Yin Yue
